Endpoints News 12. März 2026 Novo Holdings’ assets fell by a third in 2025 as Novo Nordisk’s value sank
Endpoints News 27. Feb. 2026 Novo Nordisk’s ‘strategic conundrum’: How being anchored to the past could cost it the future
Endpoints News 24. Feb. 2026 Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to market
Endpoints News 23. Feb. 2026 Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial
Endpoints News 9. Feb. 2026 Novo Nordisk sues Hims over Wegovy patent infringement, considers seeking 'hundreds of millions' in damages
Endpoints News 4. Feb. 2026 Embattled Novo Nordisk considers buying a monthly GLP-1 to bolster portfolio
Endpoints News 16. Jan. 2026 Novo Nordisk, BioMarin make AI moves; Bristol Myers welcomes neurology exec from Eisai
Endpoints News 15. Jan. 2026 A compounding pharmacy hits back at Eli Lilly, Novo Nordisk with antitrust lawsuit
Endpoints News 15. Jan. 2026 FDA to meet Novo Nordisk on troubled site; AbbVie buys drug-device factory
Endpoints News 15. Jan. 2026 Novo Nordisk Foundation to inject $850M+ into BioInnovation Institute through 2035
Endpoints News 12. Jan. 2026 #JPM26: Novo Nordisk CEO says pharma can learn from the GLP-1 compounding boom